Key takeaways
- A Mayo Clinic retrospective study presented in late 2026 reveals that menopausal hormone therapy (MHT) combined with semaglutide significantly improves and sustains weight loss compared to semaglutide alone.
- The same long-term synergistic weight-loss boost was not observed in patients taking tirzepatide with hormone therapy, possibly due to a clinical ceiling effect.
- The findings offer crucial regimen-planning and financial insights for cash-pay telehealth buyers choosing between semaglutide and tirzepatide.
- Experts emphasize that weight management is not an approved indication for MHT, and larger prospective clinical trials are needed to confirm the observational findings.
What happened
At the Menopause Society annual meeting, researchers from the Mayo Clinic presented a new retrospective cohort study showing that menopausal hormone therapy (MHT) may boost and sustain weight loss for women taking semaglutide. Led by Dr. Regina Castaneda, a postdoctoral research fellow at the Mayo Clinic in Jacksonville, Florida, the study analyzed real-world electronic health record data from 2017 through December 2025. The results revealed that women using MHT alongside semaglutide (Wegovy) lost significantly more weight than those using semaglutide alone—a synergy that surprisingly did not persist over the long term for patients taking tirzepatide (Zepbound).
Why it matters
This study provides critical regimen-planning insights for the millions of midlife women navigating weight loss during menopause, particularly cash-pay telehealth buyers looking to optimize their clinical outcomes. Menopause introduces metabolic hurdles that often make weight loss more difficult. This new data suggests that combining semaglutide with hormone therapy could help overcome these hurdles, allowing patients to achieve higher weight-loss tiers.
However, because weight management is not an official indication for menopausal hormone therapy, patients cannot obtain MHT solely to boost weight loss. Instead, for women who already have established clinical indications for hormone therapy—such as hot flashes or night sweats—the choice of which GLP-1 or dual GIP/GLP-1 agonist to pair with their treatment becomes highly consequential. For cash-paying buyers choosing between online prescription programs, this data helps clarify whether paying a premium for tirzepatide is necessary, or if a more budget-friendly semaglutide regimen yields comparable success when combined with their existing hormone therapy.
What the data says
The retrospective study evaluated data from midlife women aged 45 or older with a body mass index (BMI) of 27 kg/m² or higher who used either semaglutide or tirzepatide for at least 12 months. The researchers excluded patients with a history of bariatric surgery, active cancer, pregnancy, or those taking other concurrent obesity medications.
In the semaglutide cohort (2,379 women; 1,586 on combined therapy and 793 on semaglutide alone), the MHT group experienced significantly greater weight loss starting at the 9-month mark:
- At 9 months: -9.8% weight loss with MHT vs. -8.2% on semaglutide alone
- At 12 months: -11.0% weight loss with MHT vs. -9.5% on semaglutide alone
- At 15 months: -11.6% weight loss with MHT vs. -9.7% on semaglutide alone
Women combining semaglutide and MHT were also statistically more likely to reach higher total body weight loss milestones:
- At least 10% weight loss: 55% vs. 51%
- At least 20% weight loss: 22% vs. 18%
- At least 25% weight loss: 13% vs. 10%
- At least 30% weight loss: 6% vs. 4%
Conversely, the tirzepatide cohort (1,476 women; 492 on combined therapy and 984 on tirzepatide alone) did not see the same sustained benefit. While the combined MHT and tirzepatide group saw a modest boost in weight loss at 3 months (-6.6% vs. -5.9%), the difference disappeared at later points. The only long-term advantage for the tirzepatide MHT group was a slightly higher rate of achieving at least 5% total body weight loss (88% vs. 84%). Beyond that minimal threshold, there were no significant differences at higher weight-loss targets.
How it compares
The difference in how these two leading weight-loss drugs interact with hormone therapy highlights the distinct clinical profiles of semaglutide and tirzepatide. Tirzepatide is a dual GIP and GLP-1 receptor agonist, whereas semaglutide targets only the GLP-1 receptor. On average, tirzepatide delivers higher overall weight loss when prescribed as a monotherapy.
Dr. Castaneda suggested that tirzepatide's high baseline efficacy might create a "ceiling effect." Because tirzepatide is already highly effective at overcoming the metabolic disadvantages of menopause on its own, adding hormone therapy may offer very little room for further measurable improvement.
For online cash buyers, this distinction is financially meaningful. Brand-name Zepbound and Wegovy both carry list prices exceeding $1,000 per month without insurance. In the telehealth market, where patients turn to compounded alternatives or cash-pay memberships, tirzepatide is routinely priced higher than semaglutide. A typical monthly supply of compounded tirzepatide often ranges from $300 to $450, whereas compounded semaglutide is widely available for $200 to $300 per month.
For a menopausal woman paying out-of-pocket, this Mayo Clinic data suggests that choosing the less expensive semaglutide alongside her existing hormone therapy could bridge the efficacy gap, delivering superior, sustained results without the higher monthly cost of a tirzepatide regimen. To explore current cash pricing and telehealth options, buyers can consult the CompareRx interactive provider comparison tool and read our guide to the cheapest telehealth GLP-1 programs.
How this fits the bigger picture
This study adds to an expanding scientific focus on how gender, hormones, and life stages impact patient responses to obesity treatments. As weight management eclipses all other medical uses for GLP-1 therapies in the US, understanding these patient-specific variables is more urgent than ever. We previously detailed this massive market shift in our coverage of how GLP-1 weight loss use overtakes all other medical uses, which continues to reshape telehealth offerings and retail drug demand.
The Mayo Clinic findings also parallel other clinical developments highlighting gender-specific weight-loss drug performance. For instance, as analyzed in our report on how Novo CagriSema drives 25% weight loss for women, next-generation combination therapies are demonstrating unprecedented efficacy specifically across all menopausal stages.
While brand-name drug manufacturers continue to target postmenopausal biology with new molecular formulations, the Mayo Clinic data suggests that existing, widely accessible hormone therapies may already optimize the performance of standard semaglutide. For cash-paying consumers seeking maximum value, this real-world interaction underscores the necessity of discussing entire health profiles—including hormone replacement regimens—with telehealth providers during initial consultations.
What happens next
Because this research was a retrospective observational study, it cannot prove a direct, causal relationship between hormone therapy and enhanced semaglutide performance. Dr. Castaneda and other experts, including former Menopause Society president Dr. JoAnn E. Manson, emphasize that these findings must be confirmed by prospective, randomized clinical trials.
Future research will need to examine how different hormone therapy formulations, delivery methods (such as oral pills versus transdermal patches), and the timing of therapy relative to the onset of menopause impact weight loss. Additionally, researchers aim to look beyond BMI to measure how combined therapies affect visceral fat, muscle mass preservation, bone health, and long-term cardiovascular outcomes. For now, menopausal patients should coordinate closely with their primary care physicians and telehealth clinicians to evaluate their overall treatment plan.
Disclaimer: CompareRx does not provide medical advice. Always consult a qualified healthcare professional before starting, stopping, or altering any medication or hormone therapy regimen.